Valink Therapeutics, a biotechnology company pioneering next-generation oncology therapeutics, announced it has closed an $11.8 million pre-A financing round to accelerate development of its bispecific antibody-drug conjugate (bsADC) pipeline and expand its presence in the United States with new headquarters in Cambridge, Massachusetts.
The funding will be used to advance Valink’s pipeline of first-in-class treatments designed to enhance efficacy, safety, and precision in addressing complex cancer indications. The company’s bsADC technology aims to overcome the limitations of conventional ADCs by integrating novel targeting mechanisms with improved payload delivery.
The round was led by redalpine, with participation from new investors LongeVC and Oxford Science Enterprises. Existing backers RV Invest, p53 Invest, and Hoxton Ventures also contributed.
Valink is also developing complementary therapeutic modalities to broaden its impact beyond oncology. Its proprietary discovery engine and V-gate™ approach allow fine-tuned target control and programmable biology, offering potential for multispecific or multifunctional ADCs and multivalent agonists across solid tumor indications, including colorectal cancer.
Founded to reimagine targeted oncology treatments, Valink is now advancing two oncology programs into preclinical development. The company’s U.K. R&D subsidiary, Valink Therapeutics Ltd, continues to serve as a core base for scientific development and collaboration.
KEY QUOTES:
“We are grateful to redalpine and our syndicate of new and existing investors for their confidence in our vision and strategy. This financing strengthens our position as a leader in next-generation bispecific ADCs and supports the advancement of our oncology pipeline toward key milestones. Our V-gate approach and proprietary drug discovery engine expand the frontier of antibody drug conjugates, offering the potential for first-in-class medicines to address areas of high unmet need in oncology and beyond.”
Arne Scheu, DPhil, Co-founder and Chief Executive Officer, Valink Therapeutics
“At redalpine, we back technologies that reshape paradigms. Valink’s discovery platform and V-gate approach represent a compelling advancement on traditional ADC strategies, unlocking new therapeutic possibilities by fusing programmable biology and a novel framework for target synergy. We’re excited to lead this round and support Valink’s mission to address real-world disease biology with precision and adaptability.”
Michael Sidler, Founding Partner, redalpine, and Member of the Board of Directors, Valink Therapeutics
